Protagenic & Phytanix Merge in All-Stock Move, Sparking Retail Frenzy
Protagenic Therapeutics (NASDAQ: PTIX) just pulled off a biotech plot twist worthy of a season finale.
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Citadel Investment Group Ken Griffin | 0 | $0 | 0% |
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.81 | 8,000 | $6,480.00 | 45,815 | 2023-10-12 | Filing | |
| $0.72 | 8,000 | $5,760.00 | 151,260 | 2022-05-18 | Filing | |
| $0.71 | 23,000 | $16,330.00 | 143,260 | 2022-05-17 | Filing | |
| $2.29 | 1,000 | $2,290.00 | 120,260 | 2021-04-30 | Filing | |
| $2.29 | 1,000 | $2,290.00 | 119,260 | 2021-04-29 | Filing |
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 41,783 | $28,307 | 0% | |
| 2. | 100 | $68 | 0% | |
| 3. | 25,000 | $16 | 0.01% | |
| 4. | 17 | $12 | 0% | |
| 5. | 0 | $0 | 0% |